Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial
Status:
Terminated
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
COPD is a major public health problem and will shortly become the third most common cause of
global mortality. There are currently no treatments that can meaningfully alter the
progression of COPD or the time to death. Consequently novel therapeutic strategies for COPD
are urgently required. This will be a randomised, double-blind, placebo-controlled, trial of
Epstein-Barr virus suppression in COPD. Participants will be randomised to receive
valaciclovir 1 gram three times daily for 8 weeks or matching placebo. The study will measure
EBV suppression using quantitative PCR. Secondary outcomes will include Lung function quality
of life and drug tolerability. The exploratory analysis will evaluate biomarkers of airway
inflammation within the sputum and blood.
Phase:
Phase 2
Details
Lead Sponsor:
Belfast Health and Social Care Trust
Collaborators:
Northern Ireland Clinical Trials Unit Queen's University, Belfast